APTO News and Press, Aptose Biosciences Inc. From 05/09/23

2023-05-09 10:27:43 ET Aptose Biosciences press release ( NASDAQ: APTO ): Q1 GAAP EPS of -$0.15 misses by $0.03 . Total cash and cash equivalents and investments as of March 31, 2023, were $35.7 million. Based on current operations, the Company expects that cash on han...

2023-05-08 21:22:07 ET Aptose Biosciences Inc. (APTO) Q1 2023 Earnings Conference Call May 08, 2023 5:00 PM ET Company Participants Susan Pietropaolo – Corporate Communications & Investor Relations William G. Rice – Chairman, President and Chief Exe...

─ Tuspetinib Dose Escalation and Dose Exploration Trial Completed and Delivered Clinical Responses as Monotherapy Over Four Dose Levels in Very Difficult to Treat AML Patient Populations ─ ─ Doublet of Tuspetinib and Venetoclax Dosing Underway for Relapsed/Ref...

SAN DIEGO and TORONTO, May 04, 2023 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical- stage precision oncology company developing highly differentiated oral targeted agents to treat hematologic malignancies, today announced that William G. Rice, Ph.D., Chairman, Pr...

SAN DIEGO and TORONTO, April 24, 2023 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical- stage precision oncology company developing highly differentiated oral targeted agents to treat hematologic malignancies, will report financial results for the first quarter end...

SAN DIEGO and TORONTO, April 10, 2023 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral kinase inhibitors to treat hematologic maligna...

SAN DIEGO and TORONTO, March 28, 2023 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral kinase inhibitors to treat hematologic malignancies, today announced that the company will be participating...

2023-03-23 22:07:09 ET Aptose Biosciences Inc. (APTO) Q4 2022 Earnings Conference Call March 23, 2023, 05:00 PM ET Company Participants Susan Pietropaolo - Managing Director William Rice - Chairman, President and CEO Fletcher Payne - SVP and Chief Financial Offic...

2023-03-23 16:48:17 ET Aptose Biosciences press release ( NASDAQ: APTO ): FY GAAP EPS of -$0.45 beats by $0.01 . Total cash and cash equivalents and investments as of December 31, 2022, were $47.0 million. Based on current operations, Aptose expects that cash on hand a...

─ APTIVATE Expansion Trial of Tuspetinib as Single Agent in Relapsed/Refractory AML Patients is Up and Running; Initiated Enrollment of Combination Treatment Arm with Venetoclax ─ ─ RAS Mutated AML Clinically Sensitive to Tuspetinib ─ ─ Continu...